[1] |
CHEN Chenxin, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, HE Jia.
Combination of zero-inflated model and Dirichlet process in detection of adverse reaction signals during post-marketing surveillance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 651-654.
|
[2] |
TIAN Chunhua, WU Guizhi.
Implementation of periodic benefit risk evaluation reports in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384.
|
[3] |
LIU Caiping, CHAO Bao, FENG Yuanzhou, SUN Lan, LUO Yuan, YANG Jingfeng, DONG Wu, WANG Yongan, LI Yueting, ZHAO Baoquan.
Establishment of transgenic zebrafish model regulated by nr1h4 and related studies
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 873-880.
|
[4] |
ZHANG Qiang, DU Pengcheng, MAN Chunrui, SUN Qian.
Network pharmacology of protection against angina pectoris by Ginkgo Biloba
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 158-163.
|
[5] |
YANG Xiaolu, CAO Shan, XIONG Bo, QIN Zhen, XIA Yun, QU Hong.
One case of serious liver injury induced by Xiaojin tablets
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 213-216.
|
[6] |
Anna C Zhao-Wong, ZHU Lilin.
An introduction to the Medical Dictionary for Regulatory Activities and its use
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 74-78.
|
[7] |
SUN Qian, CHEN Hong, GUO Xinxin, LIU Shengwei, LIAO Yuan, JIA Lingling.
Network Pharmacology of Luteolin Protecting against Cerebral Ischemia
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 760-762.
|
[8] |
LIU Cuili, TIAN Chuanhua, XIA Dongsheng, ZHU Lan, LIU Hongliang, SHEN Changhui, QI Yan, WANG Tao.
Considerations about MedDRA Coding in Adverse Drug Reaction Reports
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1055-1057.
|
[9] |
YANG Yue.
Implementation of Pharmacovigilance System in Drug Administration Law and Application of ICH E2 Guideline
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 65-71.
|
[10] |
LIU Lei, ZHANG Qiongling, WANG Jiyong, DING Shilan, YOU Yun, XIAO Suping.
Bioassay on Aquatic Extract of Processed Radix Aconiti Carmichaeli
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 75-80.
|
[11] |
HOU Yongfang, TIAN Chunhua, LIU Hongliang, LIU Cuili, LI Ming, WANG Xinmin.
Study on Applicability of ICH Guideline M1 Mapping Practice of National Adverse Drug Reaction Terminology
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 333-337.
|
[12] |
MA Danhua, LIU Hongliang, WANG Dan, LI Ming, TIAN Chunhua.
Study on Applicability of ICH Guideline M1 Mapping Feasibility of National Adverse Drug Reaction Terminology
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(6): 329-332.
|
[13] |
HOU Yong-fang, DONG Duo, XIONG Wei-yi, LI Lan, LIU Hong-liang, LIU Rui, WAN Bang-xi.
Developement of ICSR E2B Guideline
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(3): 144-146.
|
[14] |
ZHANG Xue-mei, GUO Jia-dong, FENG Bian-ling, YANG Shi-min.
Investigation on Work State of Adverse Drug Reaction Reporting in Some West Provinces
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(12): 740-743.
|
[15] |
LI Qing-na,LU Fang,ZHAO Yang,GAO Hong-yang,GAO Rui.
A Preliminary Study on Establishing the Set of Terms for Coding Clinical Trials of TCM Based on MedDRA Terminology
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(1): 53-55.
|